608d8ca8-8eeb-40a1-a95b-57eefcabbdab
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 63
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFUI-TTM1-A-1-0-R-A743-41 | — | C | 0.870 |
| 2 | ad16ffcf-fd80-4008-9309-c4fe1e757507 | — | — | 0.860 |
| 3 | 49df6599-2159-457c-a94f-980cab788dbf | — | — | 0.856 |
| 4 | f5174c29-918d-4ad9-bd44-c94463396414 | — | — | 0.852 |
| 5 | BS_49FQXT2E | high-grade glioma | — | 0.850 |
| 6 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.848 |
| 7 | AUR-AFR2-TTP1-A-1-1-R-A742-41 | — | C | 0.846 |
| 8 | TCGA-35-4122-01A-01R-1107-07 | — | cohortA1 | 0.843 |
| 9 | SRR8518165 | — | C | 0.837 |
| 10 | 3fa3af13-58f0-4c5b-b009-f6f936fb07b5 | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |